Navigation Links
PDL BioPharma Announces Fourth Quarter and Full Year 2011 Financial Results
Date:2/23/2012

INCLINE VILLAGE, Nev., Feb. 23, 2012 /PRNewswire/ -- PDL BioPharma, Inc. (PDL) (NASDAQ: PDLI) today reported financial results for the fourth quarter and full year ended December 31, 2011.

(Logo:  http://photos.prnewswire.com/prnh/20110822/SF55808LOGO)

Total revenues in 2011 were $362 million, compared to $345 million in 2010, with royalty revenues increasing two percent over full year 2010. For the fourth quarter of 2011, total revenues were $72.8 million, compared to $76.1 million in the fourth quarter of 2010.

Royalty revenues for the fourth quarter of 2011 are based on third quarter product sales by PDL's licensees. The fourth quarter 2011 revenue decline is primarily driven by reduced royalties from third quarter 2011 sales of Avastin® and Herceptin®, which are marketed by Genentech and Roche, partially offset by increased royalties from third quarter 2011 sales of Lucentis® which is marketed by Genentech and Novartis, and Tysabri®, which is marketed by Elan and Biogen Idec. Royalty revenue for the fourth quarter and 2011 are net of payments made under our February 2011 settlement agreement with Novartis Pharma AG.

Operating expenses in 2011 were $18.3 million, compared with $133.9 million in 2010. Included in operating expenses in 2010 is a $92.5 million legal settlement with MedImmune and $41.4 million in general and administrative expenses. For the fourth quarter of 2011, general and administrative expenses were $4.8 million compared with $12.1 million for the same period of 2010.

Net income in 2011 was $199.4 million, or $1.15 per diluted share as compared with net income of $91.9 million in 2010 or $0.54 per diluted share. Net income for the fourth quarter of 2011 was $38.9 million or $0.24 per diluted share as compared with a n
'/>"/>

SOURCE PDL BioPharma, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related biology technology :

1. Keryx Biopharmaceuticals, Inc. to Hold Conference Call on Second Quarter 2008 Financial Results on Monday, August 11, at 8:30 A.M. EDT
2. Canopus Biopharma and Leading Chinese Researcher Team Up to Treat Avian Influenza, to Prevent Possible Pandemic
3. Ondine Biopharma Announces Second Quarter 2008 Financial Results
4. ARCA biopharma Appoints William R. Hiatt as Director of Clinical and Regulatory Strategy
5. XTL Biopharmaceuticals Receives Notice of Non-Compliance with Nasdaq Marketplace Rule Due to Changes in Board Composition
6. Leading Biopharmas Will Deliver Case Studies on Achieving Productivity Excellence through Engagement, Technology, Other Tools
7. Therapure Biopharma Inc. opens for business with first client contracts
8. Top Biopharma Company Adopts BioFortis Translational Research Software for Centralized Management and Mining of Clinical Biomarker Data
9. China Biopharma Effects 1 for 100 Reverse Stock Split
10. Cyntellect Launches CellXpress(TM) System to Boost Productivity of Biopharmaceutical Process Development
11. FDA Accepts New Drug Application for Bucindolol, A Genetically-Targeted Treatment for Heart Failure From ARCA biopharma
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/26/2014)... Genedata, a leading provider of ... science research, today announced the Genedata Screener® ... in Asia, Europe, and North America during September ... leading research organizations will gather for annual User ... and upcoming challenges in all areas of screening. ...
(Date:8/26/2014)... Aug. 26, 2014  That,s Nice LLC, a research-focused ... announced the formation of a new dedicated team that ... expanded team will combine current and new staff in ... Nice. Guy Tiene has ... the team. Tiene was previously Director of Marketing for ...
(Date:8/26/2014)... MA (PRWEB) August 26, 2014 ... solutions, today announced the release of Transform for ... for Electronic Data Capture (EDC) product line. It ... XClinical, and allows integration with MARVIN, the EDC ... as reducing study setup time, by allowing instantaneous ...
(Date:8/26/2014)... 2014 Talon Innovations, a provider of ... Semiconductor, Medical Device, Aerospace and other technology-driven industries, announces ... Business magazine’s fourth annual Manufacturing Award in the category ... February that Talon received a grant from the Minnesota ... new training program for its employees. , ...
Breaking Biology Technology:Thought Leaders to Explore Innovations in SPR & Combination Screening at Genedata Screener User Group Meetings 2Thought Leaders to Explore Innovations in SPR & Combination Screening at Genedata Screener User Group Meetings 3That's Nice Announces Expanded Offering For Strategic Content And Public Relations 2That's Nice Announces Expanded Offering For Strategic Content And Public Relations 3Introducing Transform for MARVIN: Providing Further Flexibility for CROs and Sponsors in Partnership with XClinical 2Talon Innovations Selected as Finalist for Minnesota Business Magazine Award 2Talon Innovations Selected as Finalist for Minnesota Business Magazine Award 3
... top line data from a Phase 2 clinical trial ... of Influenza-Like Illness (ILI) caused by all types and ... strains. In a double-blind, placebo-controlled, Phase 2 trial of ... DAS181 resulted in a significant reduction in patients, influenza ...
... (July 1, 2011) After Fukushima, it is now imperative ... from cradle to grave. If nuclear waste management is not ... will reject nuclear power as an energy choice, according to ... Atomic Scientists , published by SAGE. According to Allison ...
... just fifteen minutes to analyze a sample suspected of ... The technology amplifies any anthrax DNA present in the ... microscopic cells of the deadly bacteria Bacillus anthracis. ... lethal microbe that might be used intentionally to infect ...
Cached Biology Technology:NexBio Reports Safety and Significant Antiviral Activities of DAS181 (Fludase)* from a Dose-Ranging Phase II Clinical Trial 2NexBio Reports Safety and Significant Antiviral Activities of DAS181 (Fludase)* from a Dose-Ranging Phase II Clinical Trial 3NexBio Reports Safety and Significant Antiviral Activities of DAS181 (Fludase)* from a Dose-Ranging Phase II Clinical Trial 4Nuclear waste requires cradle-to-grave strategy 2Nuclear waste requires cradle-to-grave strategy 3Nano detector for deadly anthrax 2
(Date:8/26/2014)... St. Louis have developed algorithms to identify weak spots ... breaking. The technology, which needs to be refined before ... pinpoint minor strains and tiny injuries in the body,s ... is available online Aug. 27 in the Journal ... at the nexus of the physical and life sciences. ...
(Date:8/26/2014)... a colony of harmful bacteria, biofilms make the ... in a biofilm pose a significant health risk ... treatment, and biofilm-protected bacteria account for some 80 ... are 50 to 1,000 times more resistant to ... we may have stumbled onto a magic bullet," ...
(Date:8/26/2014)... have provided the first evidence that the lack ... early signs of dementia. , Published in ... absence of the protein MK2/3 promotes structural and ... These changes were shown to have a significant ... learning and memory formation capabilities. , An absence ...
Breaking Biology News(10 mins):New technology may identify tiny strains in body tissues before injuries occur 2New technology may identify tiny strains in body tissues before injuries occur 3Breakthrough antibacterial approach could resolve serious skin infections 2Breakthrough antibacterial approach could resolve serious skin infections 3Lack of naturally occuring protein linked to dementia 2
... Island of New Zealand is marked at approximately 38 S ... line". This region forms the southern distributional limit of many ... number of endemic plants are found there. Ecologists have recently ... the "kauri line". Wetlands serve vital ecological functions by ...
... and from Berkeley have used metal complexes to modify ... Chemical Society , they report for the first time ... "With this work, we have laid the molecular foundation ... Stoll from the Faculty of Chemistry and Biochemistry at ...
... MAResearchers from Brigham and Women,s Hospital (BWH) have made a ... The team, led by Thomas S. Kupper, MD, chair of ... that high expression of a cell-signaling molecule, known as interleukin-9, ... findings will be published online in the July 8, 2012 ...
Cached Biology News:A new species of wirerush from the wetlands in northern New Zealand 2A new avenue to better medicines: Metal-peptide complexes 2Researchers discover molecule in immune system that could help treat dangerous skin cancer 2
Applications: Immunohistochemistry, ISH, FISH, CISH....
Immunogen: Synthetic peptide (KLH conjugated): L(506) S K S S S Q I R M S G L P A D N L A T(525) Storage: -20 C, Avoid Freeze/Thaw Cycles...
Attachments: Clip bar for tubes 10 to 19 mm in diameter Overall Dimension Height IC: 6 (15.2) Overall Dimension Length IC: 18.5 (46.9) Overall Dimension Width IC: 4 (10.2)...
BD FastImmune EDTA Solution. Applications: Flow Cytometry Storage Temperature: Refrigerate(2 to 8C)...
Biology Products: